AlphaFold predicted structure
ATXN7L3 · Q14CW9

Mean pLDDT
65.4/ 100
Low
347 residues
Confidence breakdown
- Very high(≥ 90)14%
- Confident(70–90)28%
- Low(50–70)26%
- Very low(< 50)32%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
ataxin 7 like 3
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
DDG2P
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownIntellectual disability
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownneurodegenerative disease
hepatocellular carcinoma
retinitis pigmentosa
Cone rod dystrophy
Familial exudative vitreoretinopathy
Leber congenital amaurosis
sleep apnea syndrome
Bardet-Biedl syndrome
central areolar choroidal dystrophy
oculocutaneous albinism type 2
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Ataxin-7-like protein 3
Component of the transcription regulatory histone acetylation (HAT) complex SAGA, a multiprotein complex that activates transcription by remodeling chromatin and mediating histone acetylation and deubiquitination. Within the SAGA complex, participates in a subcomplex that specifically deubiquitinates both histones H2A and H2B (PubMed:18206972, PubMed:21746879). The SAGA complex is recruited to specific gene promoters by activators such as MYC, where it is required for transcription. Required for nuclear receptor-mediated transactivation. Within the complex, it is required to recruit USP22 and ENY2 into the SAGA complex (PubMed:18206972). Regulates H2B monoubiquitination (H2Bub1) levels. Affects subcellular distribution of ENY2, USP22 and ATXN7L3B (PubMed:27601583)
ATXN7L3 · Q14CW9

Mean pLDDT
65.4/ 100
Low
347 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0